Table 1. Patient and lesion characteristics.
|
Characteristic | |
| Number of patients total |
23 |
| Age median (range) |
59 (46–82) |
|
Gender, number of patients (%) | |
| Male | 13 (56.5%) |
| Female |
10 (43.5%) |
|
Histology | |
| Clear cell RCC |
23 (100%) |
|
Treatment, number of patients (%) | |
| Sunitinib | 14 (60.9%) |
| Pazopanib | 5 (21.7%) |
| Cediranib | 2 (8.7%) |
| Regorafenib |
2 (8.7%) |
|
Lesions, number of lesions (%) | |
| Lung/pleura | 18 (32.1%) |
| Lymph node | 11 (19.6%) |
| Liver | 11 (19.6%) |
| Adrenal gland | 8 (14.3%) |
| Pancreas | 5 (8.9%) |
| Other site |
3 (5.4%) |
|
Baseline characteristics of the lesions, median (range) | |
| Longest diameter of lesion | 28.5 (10 to 111.4) mm |
| Volume of lesion | 7.95 (0.21 to 317.2) ml |
| Mean enhancement of lesion | 93 (35 to 242) HU |
| Normalised mean enhancement (nE) of lesion |
0.372 (0.136 to 0.650) nHU |
|
Lesion response, baseline to first on-treatment scan median (range) | |
| Percentage change in diameter | −8.2 (−73.2 to +73.8)% |
| Percentage change in nE | −41.3 (−87.3 to +57.9)% |
Abbreviations: HU=Hounsfield Units; nHU=normalised mean Hounsfield Units; RCC=renal cell carcinoma.